The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.
Identifieur interne : 000927 ( Main/Corpus ); précédent : 000926; suivant : 000928The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.
Auteurs : P. Mu Oz ; A. Galar ; P. Catalán ; M. Valerio ; T. Aldamiz-Echevarría ; C. C Lliga ; E. BouzaSource :
- Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [ 1988-9518 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Age Distribution (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Betacoronavirus (MeSH), Body Mass Index (MeSH), Child (MeSH), Clinical Laboratory Techniques (MeSH), Comorbidity (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (mortality), Female (MeSH), Fever (etiology), Follow-Up Studies (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (mortality), Spain (epidemiology), Symptom Assessment (MeSH), Time Factors (MeSH), Young Adult (MeSH).
- MESH :
- geographic , epidemiology : Spain.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- etiology : Fever.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Hospitalization.
- Adult, Age Distribution, Aged, Aged, 80 and over, Betacoronavirus, Body Mass Index, Child, Clinical Laboratory Techniques, Comorbidity, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pandemics, Symptom Assessment, Time Factors, Young Adult.
Abstract
OBJECTIVE
There are few descriptions of the clinical presentation and evolution of consecutive SARS-CoV-2 infections with a long-enough follow up.
METHODS
Description of the first consecutive 100 patients with microbiologically-proven COVID-19 in a large hospital in Madrid, Spain including a minimum of two-month follow up.
RESULTS
The median age of the patients (52% males) was 61.5 years (IQR=39.5-82.0) and the median BMI was 28.8 kg/m2 (IQR=24.7-33.7). Overall 72% of the patients had one or more co-morbid conditions with a median age-adjusted Charlson index of 2 (IQR=0-5.7). Five patients (5%) were immunosuppressed. The most common symptoms at the time of diagnosis were fever (80.0%), cough (53.0%) and dyspnea (23.0%). The median O2 saturation at the time of first examination was 94% (IQR=90-97). Chest X-ray on admission was compatible with pneumonia in 63% of the cases (bilateral in 42% and unilateral in 21%). Overall, 30% were managed at home and 70% were admitted to the hospital. Thirteen patients were admitted to the ICU with a median of 11 days of stay in the Unit (IQR=6.0-28.0). CALL score of our population ranged from 4 to 13. Overall, 60.0% of patients received antibiotic treatment and 66.0%, empirical antiviral treatment, mainly with lopinavir/ritonavir (65%) or hydroxychloroquine (42%). Mortality, with a minimum of 60 days of follow up, was 23%. The median age of the deceased patients was 85 years (IQR=79-93).
CONCLUSIONS
We found a high mortality in the first 100 patients diagnosed with COVID-19 at our institution, associated with advanced age and the presence of serious underlying diseases.
DOI: 10.37201/req/072.2020
PubMed: 32729288
PubMed Central: PMC7528411
Links to Exploration step
pubmed:32729288Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.</title>
<author><name sortKey="Mu Oz, P" sort="Mu Oz, P" uniqKey="Mu Oz P" first="P" last="Mu Oz">P. Mu Oz</name>
</author>
<author><name sortKey="Galar, A" sort="Galar, A" uniqKey="Galar A" first="A" last="Galar">A. Galar</name>
<affiliation><nlm:affiliation>Alicia Galar, Servicio de Microbiología y E. Infecciosas, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo, 46, 28007 Madrid, Spain. alicia.galar@salud.madrid.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Catalan, P" sort="Catalan, P" uniqKey="Catalan P" first="P" last="Catalán">P. Catalán</name>
</author>
<author><name sortKey="Valerio, M" sort="Valerio, M" uniqKey="Valerio M" first="M" last="Valerio">M. Valerio</name>
</author>
<author><name sortKey="Aldamiz Echevarria, T" sort="Aldamiz Echevarria, T" uniqKey="Aldamiz Echevarria T" first="T" last="Aldamiz-Echevarría">T. Aldamiz-Echevarría</name>
</author>
<author><name sortKey="C Lliga, C" sort="C Lliga, C" uniqKey="C Lliga C" first="C" last="C Lliga">C. C Lliga</name>
</author>
<author><name sortKey="Bouza, E" sort="Bouza, E" uniqKey="Bouza E" first="E" last="Bouza">E. Bouza</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32729288</idno>
<idno type="pmid">32729288</idno>
<idno type="doi">10.37201/req/072.2020</idno>
<idno type="pmc">PMC7528411</idno>
<idno type="wicri:Area/Main/Corpus">000927</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000927</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.</title>
<author><name sortKey="Mu Oz, P" sort="Mu Oz, P" uniqKey="Mu Oz P" first="P" last="Mu Oz">P. Mu Oz</name>
</author>
<author><name sortKey="Galar, A" sort="Galar, A" uniqKey="Galar A" first="A" last="Galar">A. Galar</name>
<affiliation><nlm:affiliation>Alicia Galar, Servicio de Microbiología y E. Infecciosas, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo, 46, 28007 Madrid, Spain. alicia.galar@salud.madrid.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Catalan, P" sort="Catalan, P" uniqKey="Catalan P" first="P" last="Catalán">P. Catalán</name>
</author>
<author><name sortKey="Valerio, M" sort="Valerio, M" uniqKey="Valerio M" first="M" last="Valerio">M. Valerio</name>
</author>
<author><name sortKey="Aldamiz Echevarria, T" sort="Aldamiz Echevarria, T" uniqKey="Aldamiz Echevarria T" first="T" last="Aldamiz-Echevarría">T. Aldamiz-Echevarría</name>
</author>
<author><name sortKey="C Lliga, C" sort="C Lliga, C" uniqKey="C Lliga C" first="C" last="C Lliga">C. C Lliga</name>
</author>
<author><name sortKey="Bouza, E" sort="Bouza, E" uniqKey="Bouza E" first="E" last="Bouza">E. Bouza</name>
</author>
</analytic>
<series><title level="j">Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</title>
<idno type="eISSN">1988-9518</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Age Distribution (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Body Mass Index (MeSH)</term>
<term>Child (MeSH)</term>
<term>Clinical Laboratory Techniques (MeSH)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Female (MeSH)</term>
<term>Fever (etiology)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>Hospitalization (statistics & numerical data)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Spain (epidemiology)</term>
<term>Symptom Assessment (MeSH)</term>
<term>Time Factors (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fever</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Age Distribution</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Betacoronavirus</term>
<term>Body Mass Index</term>
<term>Child</term>
<term>Clinical Laboratory Techniques</term>
<term>Comorbidity</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Symptom Assessment</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>There are few descriptions of the clinical presentation and evolution of consecutive SARS-CoV-2 infections with a long-enough follow up.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Description of the first consecutive 100 patients with microbiologically-proven COVID-19 in a large hospital in Madrid, Spain including a minimum of two-month follow up.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The median age of the patients (52% males) was 61.5 years (IQR=39.5-82.0) and the median BMI was 28.8 kg/m2 (IQR=24.7-33.7). Overall 72% of the patients had one or more co-morbid conditions with a median age-adjusted Charlson index of 2 (IQR=0-5.7). Five patients (5%) were immunosuppressed. The most common symptoms at the time of diagnosis were fever (80.0%), cough (53.0%) and dyspnea (23.0%). The median O2 saturation at the time of first examination was 94% (IQR=90-97). Chest X-ray on admission was compatible with pneumonia in 63% of the cases (bilateral in 42% and unilateral in 21%). Overall, 30% were managed at home and 70% were admitted to the hospital. Thirteen patients were admitted to the ICU with a median of 11 days of stay in the Unit (IQR=6.0-28.0). CALL score of our population ranged from 4 to 13. Overall, 60.0% of patients received antibiotic treatment and 66.0%, empirical antiviral treatment, mainly with lopinavir/ritonavir (65%) or hydroxychloroquine (42%). Mortality, with a minimum of 60 days of follow up, was 23%. The median age of the deceased patients was 85 years (IQR=79-93).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>We found a high mortality in the first 100 patients diagnosed with COVID-19 at our institution, associated with advanced age and the presence of serious underlying diseases.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32729288</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1988-9518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</Title>
<ISOAbbreviation>Rev Esp Quimioter</ISOAbbreviation>
</Journal>
<ArticleTitle>The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.</ArticleTitle>
<Pagination><MedlinePgn>369-378</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">munoz30jul2020</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.37201/req/072.2020</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There are few descriptions of the clinical presentation and evolution of consecutive SARS-CoV-2 infections with a long-enough follow up.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Description of the first consecutive 100 patients with microbiologically-proven COVID-19 in a large hospital in Madrid, Spain including a minimum of two-month follow up.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the patients (52% males) was 61.5 years (IQR=39.5-82.0) and the median BMI was 28.8 kg/m2 (IQR=24.7-33.7). Overall 72% of the patients had one or more co-morbid conditions with a median age-adjusted Charlson index of 2 (IQR=0-5.7). Five patients (5%) were immunosuppressed. The most common symptoms at the time of diagnosis were fever (80.0%), cough (53.0%) and dyspnea (23.0%). The median O2 saturation at the time of first examination was 94% (IQR=90-97). Chest X-ray on admission was compatible with pneumonia in 63% of the cases (bilateral in 42% and unilateral in 21%). Overall, 30% were managed at home and 70% were admitted to the hospital. Thirteen patients were admitted to the ICU with a median of 11 days of stay in the Unit (IQR=6.0-28.0). CALL score of our population ranged from 4 to 13. Overall, 60.0% of patients received antibiotic treatment and 66.0%, empirical antiviral treatment, mainly with lopinavir/ritonavir (65%) or hydroxychloroquine (42%). Mortality, with a minimum of 60 days of follow up, was 23%. The median age of the deceased patients was 85 years (IQR=79-93).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found a high mortality in the first 100 patients diagnosed with COVID-19 at our institution, associated with advanced age and the presence of serious underlying diseases.</AbstractText>
<CopyrightInformation>©The Author 2020. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muñoz</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Galar</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Alicia Galar, Servicio de Microbiología y E. Infecciosas, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo, 46, 28007 Madrid, Spain. alicia.galar@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catalán</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Valerio</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Aldamiz-Echevarría</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cólliga</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bouza</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><CollectiveName>Gregorio Marañón Microbiology-ID COVID 19 Study Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Spain</Country>
<MedlineTA>Rev Esp Quimioter</MedlineTA>
<NlmUniqueID>9108821</NlmUniqueID>
<ISSNLinking>0214-3429</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000657964">COVID-19 diagnostic testing</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32729288</ArticleId>
<ArticleId IdType="doi">10.37201/req/072.2020</ArticleId>
<ArticleId IdType="pmc">PMC7528411</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 May 13;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32402056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Invest. 2020 Jun;50(6):e13258</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 29;369:m1996</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32471884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 1994 Nov;47(11):1245-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7722560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diagnosis (Berl). 2020 May 26;7(2):91-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32352401</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2020 Jun;26(6):767-772</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32304745</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1574-1581</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105946</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32199877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):769-777</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32176772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 26;323(20):2052-2059</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Apr;80(4):388-393</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32112884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Einstein (Sao Paulo). 2020 Apr 09;18:eED5720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32294704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Swiss Med Wkly. 2020 Apr 29;150:w20262</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32347963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):425-434</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Mar 30;35(12):e132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32233161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 26;323(20):1999</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32453363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):147-178</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32209384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):748-755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32239127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):888-889</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32211771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1835</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Disaster Med Public Health Prep. 2020 Mar 31;:1-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32228738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 21;323(15):1488-1494</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 28;382(22):2081-2090</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32329971</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Sep 12;71(6):1393-1399</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32271369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Jun 6;395(10239):1763-1770</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32442528</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2020 May 6;24(1):193</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32375883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2020 Apr 07;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32255475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Apr 15;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293716</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Radiology. 2020 Aug;296(2):E32-E40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32101510</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000927 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000927 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32729288 |texte= The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32729288" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
This area was generated with Dilib version V0.6.37. |